Key result
FX06 cuts infarct size ~50% in a rat model of myocardial I/R injury.
Why the study?
Myocardial ischemia–reperfusion injury remains a major contributor to infarct expansion and adverse cardiac remodeling despite advances in timely reperfusion therapy.
RCT
not specified
Effect estimate: ~50% reduction in infarct size in rat model; trial outcome in humans not quantified
This review highlights the complex, interconnected mechanisms of myocardial ischemia-reperfusion injury and emphasizes the need for integrated, multi-target cardioprotective therapies to improve clinical outcomes in acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Investigational FX06 should not alter primary PCI practice; leaves open multi-target therapies for interconnected I/R injury.
Han et al. (2026) conducted an RCT in Acute ST-Segment Elevation Myocardial Infarction (STEMI) undergoing primary PCI. FX06 (human fibrin-derived peptide Bβ15–42) vs. placebo or standard care was evaluated on Reduction in necrotic core zone of affected myocardium by mitigating reperfusion injury (~50% reduction in infarct size in rat model; trial outcome in humans not quantified). FX06 treatment reduced infarct size by approximately 50% in a rat model of myocardial I/R injury, with early infusion adjunct to primary PCI under investigation in humans.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: